Straits Times Index
3,316.56 -6.06 (-0.18%) S&P 500
5,304.72 +36.88 (+0.70%) Dow
39,069.59 +4.29 (+0.01%) Nasdaq
16,920.79 +184.79 (+1.10%) Bitcoin USD
68,515.19 -603.64 (-0.87%) CMC Crypto 200
1,488.99 +20.89 (+1.42%)
AGIO Dec 2024 12.500 put
| Previous close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 12.50 |
| Expiry date | 2024-12-20 |
| Day's range | 0.1500 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
ZacksHow Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43%
The mean of analysts' price targets for Agios Pharmaceuticals (AGIO) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GlobeNewswireAgios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease – – Agios to Webcast Virtual Investor Event on June 16, 2024, at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a
ZacksWall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?
The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
